

Detection of extended-spectrum beta-lactamases

Dear Editor,

We read with interest the paper on detection of extended-spectrum beta-lactamase (ESBL) producing bacteria from patients with urinary tract infections published in the recent issue of IJMM.^[1] We have three comments:

- The authors have used only ceftazidime/ceftazidime + clavulanic acid disks for screening. As per the CLSI guidelines, both ceftazidime and cefotaxime disks, alone and in combination with clavulanic acid must be used to detect ESBL production.^[2] This is because of substrate variability; some ESBLs (e.g. TEM-5) are ceftazidimases and some others (e.g. TEM-3) are cefotaximases.^[3] In a previous study, we had screened 1000 clinical isolates each of *Escherichia coli* and *Klebsiella pneumoniae* using both disks.^[4] On further analysis of our study, we found that we would have missed 9.6% of ESBL producers if we had used only ceftazidime/ceftazidime + clavulanic acid disks. Thus, we recommend that all researchers should use both the combination disks as per CLSI recommendations
- The authors have shown that the results of *E*-test correlate well with the results obtained by polymerase chain reaction (PCR). They recommend the *E*-test for confirmation of those detected as ESBL producers by the Double Disk Synergy Test (DDST). We would like to, however, add that *E*-test may not be an ideal confirmatory test for ESBL producers. There are reports that question the utility of *E*-test for detecting ESBLs as the concentration gradient in *E*-strip is not as extensive as recommended by CLSI and the test has been shown to yield many indeterminate results^[5,6]

- The authors have assessed the validity of DDST by detecting three beta-lactamase genes: *bla*CTX-M, *bla*TEM, and *bla*SHV by PCR and consider their presence in bacteria as the genetic basis for ESBL production. While all CTX-M genes code for ESBL, only 42% of TEM types and 25% of SHV types are currently known to code for ESBL phenotype.^[7] Thus, genetic validity for ESBL production cannot be inferred by mere detection of *bla*TEM or *bla*SHV genes. One needs to sequence further the entire length of the genes and confirm whether they are ESBL producing types or not.^[8]

Financial support and sponsorship

Nil.

Conflicts of interest.

There are no conflicts of interest.

References

1. Nandagopal B, Sankar S, Sagadevan K, Arumugam H, Jesudason MV, Aswathaman K, *et al.* Frequency of extended spectrum β -lactamase producing urinary isolates of Gram-negative bacilli among patients seen in a multispecialty hospital in Vellore district, India. *Indian J Med Microbiol* 2015;33:282-5.
2. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Twenty-first Informational Supplement M100-S20. Wayne, PA, USA: CLSI; 2010.
3. Bush K, Singer SB. Biochemical characteristics of extended broad spectrum beta-lactamases. *Infection* 1989;17:429-33.
4. Rao SP, Rama PS, Gurushanthappa V, Manipura R, Srinivasan K. Extended-spectrum beta-lactamases producing *Escherichia coli* and *Klebsiella pneumoniae*: A multi-centric study across Karnataka. *J Lab Physicians* 2014;6:7-13.
5. Garrec H, Drieux-Rouzet L, Golmard JL, Jarlier V, Robert J. Comparison of nine phenotypic methods for detection

- of extended-spectrum beta-lactamase production by *Enterobacteriaceae*. J Clin Microbiol 2011;49:1048-57.
6. Espinar MJ, Rocha R, Ribeiro M, Gonçalves Rodrigues A, Pina-Vaz C. Extended-spectrum β -lactamases of *Escherichia coli* and *Klebsiella pneumoniae* screened by the VITEK 2 system. J Med Microbiol 2011;60 (Pt 6):756-60.
 7. β -Lactamase Classification and Amino Acid Sequences for TEM, SHV and OXA Extended-Spectrum and Inhibitor Resistant Enzymes. Available from: <http://www.lahey.org/studies/>. [Last accessed on 2015 Apr 11].
 8. BushK. The ABCD's of β -lactamase nomenclature. J Infect Chemother 2013;19:549-59.

***PNS Rao, SR Prasad**

Department of Microbiology (PNSR), Jagadguru Jayadeva Murugarajendra Medical College, Davangere, Department of

Microbiology (SRP), Sri Devaraj Urs Medical College, Kolar, Karnataka, India

*Corresponding author (email: <sridharao@rediffmail.com>)

Received: 02-06-2015

Accepted: 21-06-2015

Access this article online	
Quick Response Code: 	Website: www.ijmm.org
	DOI: 10.4103/0255-0857.180363